1Tomek R, Vrdoljak E, Vrbanec D, et al. Croatian guidelines for prevention of chemotherapy induced nausea and vomiting [J]. Lijec Vjesn, 2009, 131(3-4): 49.
2Botrel T E, Clark O A, Clark L, et al. Efficacy of palonosetron (PAL) eompared to other semtonin inhibitors (5 - HT3R) in preventing chemotherapy - induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenie ( MoHE ) treatment: systematic review and meta- analysis[J]. Support Care Cancer, 2011, 19(6) .' 823.
3周际昌.实用肿瘤手册[M].北京:人民卫生出版社,1999:480-481.
4Hornby P J. Central neurocircuitry associated with emecis [J].AmJ Med, 2001, lll(Suppl 8A): 106s.
6Grunberg S M, Dugan M, Muss H, et al. Effectiveness of a single- day three - drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy[J]. Support Care Cancer, 2009, 17(5) : 589.
8Billio A, Morello E, Clarke M J. Serotonin receptor antago- nists for highly emetogenic chemotherapy in adults [ J ]. Cochrane Database Sys Rev, 2010, (1) : CI106272.
4Hesketh P J.Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting[J].Cancer Invest,2000,18(2):163.
5Coates A,Abraham S,Kaye S B,et al.On the receiving end-patient perception of the side-effects of cancer chemotherapy[J].Eur J Cancer Clin Oncol,1983,19(2):203.
6Dewan P,Singhal S,Harit D.Management of chemotherapy-induced nausea and vomiting[J].Indian Pediatr,2010,47(2):149.
7Navari R M.Pathogenesis based treatment of chemotherapy induced nausea and vomiting two new agents[J].J Support Oncol,2003,1(2):89.
8Bloechl-Daum B,Deuson R R,Mavros P,et al.Delayed nausea and vomiting continue to reduce patients′ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment[J].J Clin Oncol,2006,24(27):4472.
9Kaiser R,Sezer O,Papies A,et al.Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes[J].J Clin Oncol,2002,20(12):2805.
10Grunberg S M,Dugan M,Muss H,et al.Effectiveness of a single-day three-drug regimen of dexamethasone,palonosetron,and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy[J].Support Care Cancer,2009,17(5):589.
2Ito Y,Miyauchi A,Ito M,et al.Prognosis and prognostic factors of differentiated thyroid carcinoma after the appearance of metastasis refractory to radioactive iodine therapy[J].Endocr J,2014,May 27.
3Kita T,Yokoyama K,Higuchi T,et al.Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma[J].Ann Nucl Med,2004,18(4):345-349.
4Popovic M,Warr DG,Deangelis C,et al.Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting(CINV):a systematic review and metaanalysis of randomized controlled trials[J].Support Care Cancer,2014,22(6):1685-1697.
5Park SK,Cho EJ,Kang SH,et al.A randomized,double-blind study to evaluate the efficacy of ramosetron andpalonosetron for prevention of postoperative nausea and vomiting after gynecological laparoscopic surgery[J].Korean J Anesthesiol,2013,64(2):133-137.
6Herrstedt J. Antiemetics : an update and the MASCC guidelines applied in clinical practice[ J]. Nat Clin Pract Oncol,2008.5( 1 ) 132-43.
